News | August 09, 2022
Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Subscribe To Our Newsletter & Stay Updated
